Skip to main content
. Author manuscript; available in PMC: 2022 Oct 1.
Published in final edited form as: Cancer Epidemiol. 2021 Aug 2;74:101999. doi: 10.1016/j.canep.2021.101999

Figure 2. Definiens percent positive by pathologist-assigned category.

Figure 2.

The distribution of Definiens percent positive by pathologist-assigned category. The overlap between between pathologist-assigned category and Definiens percent positive varied by marker, with some exhibiting substantial overlap (ER, AR, IR, H3K27, RXR, CD163 in stroma) and others exhibiting little or no overlap (Ki67, CD8, CD20, FASN, IGF1R, pmTOR, PTEN). ER, PR, AR, IR, H3K27, VDR, RXR, CD163-tumor, EPRS, FASN, IGF1R, pmTOR, PTEN: Left panel, negative; middle panel, low positive (1–10%); right panel, positive (>10%). CD163-stroma: Left panel, low positive (1–10%); right panel, positive (>10%). No cases were manually scored as negative. Ki67: Left panel, low proliferation (≤14%); right panel, high proliferation (>14%). CD20, CD8, CD4: Left panel, low (<10%); middle panel, moderate (10–50%); right panel, high (>50%).